What 6 Analyst Ratings Have To Say About Silence Therapeutics
Portfolio Pulse from Benzinga Insights
Six analysts have provided ratings for Silence Therapeutics (NASDAQ:SLN) in the last quarter, with 2 bullish and 4 somewhat bullish ratings. The average price target is $40.0, compared to the current price of $6.5, implying an upside potential.
June 26, 2023 | 6:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Silence Therapeutics (NASDAQ:SLN) received 2 bullish and 4 somewhat bullish ratings from 6 analysts, with an average price target of $40.0, compared to its current price of $6.5.
The 6 analysts' ratings for Silence Therapeutics are mostly positive, with an average price target of $40.0, which is significantly higher than the current price of $6.5. This implies a potential upside for the stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100